Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(O)=O
InChI
InChIKey=SHGAZHPCJJPHSC-YCNIQYBTSA-N
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16456186 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f81f505-a962-414e-8612-c3ef3b159e9a | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/16921s21s22s25lbl.pdfhttp://www.drugbank.ca/drugs/DB00523Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20886lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16456186 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f81f505-a962-414e-8612-c3ef3b159e9a | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/16921s21s22s25lbl.pdfhttp://www.drugbank.ca/drugs/DB00523
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20886lbl.pdf
Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2061 |
10.0 nM [EC50] | ||
Target ID: CHEMBL2003 |
50.0 nM [EC50] | ||
Target ID: CHEMBL2061 |
195.0 nM [EC50] | ||
Target ID: CHEMBL2008 |
3.0 nM [EC50] | ||
Target ID: CHEMBL2004 |
140.0 nM [EC50] | ||
Target ID: CHEMBL2363069 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16456186 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ACCUTANE Approved UseAccutane is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition, means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Accutane should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Accutane is indicated only for those female patients who are not pregnant, because Accutane can cause severe birth defects. Launch Date1982 |
|||
Primary | Panretin gel Approved UsePanretin gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Launch Date1999 |
|||
Primary | RETIN-A Approved UseRETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. Launch Date1971 |
|||
Palliative | TRETINOIN Approved Useretinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with tretinoin. Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
314 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOTRETINOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4055 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOTRETINOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOTRETINOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.1% |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOTRETINOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
12.5 mg/kg single, oral Overdose Dose: 12.5 mg/kg Route: oral Route: single Dose: 12.5 mg/kg Sources: |
unhealthy, 29 |
Disc. AE: Cheilitis, Skin xerosis... AEs leading to discontinuation/dose reduction: Cheilitis Sources: Skin xerosis Desquamation Headache Skin xerosis |
1000 mg single, oral Overdose |
unhealthy, 31 |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea Sources: |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
DLT: Hypercalcemia, Skin toxicity... Dose limiting toxicities: Hypercalcemia (grade 4, 22.2%) Sources: Skin toxicity (grade 3, 33.3%) Anemia (grade 3, 11.1%) Thrombocytopenia (grade 3, 11.1%) Emesis (grade 3, 11.1%) Hypercalcemia (grade 3, 11.1%) |
80 mg/m2 2 times / day multiple, oral MTD Dose: 80 mg/m2, 2 times / day Route: oral Route: multiple Dose: 80 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
DLT: Hypercalcemia, Skin toxicity... Dose limiting toxicities: Hypercalcemia (grade 4, 4.3%) Sources: Skin toxicity (grade 3, 17.4%) Emesis (grade 3, 4.3%) AST/ALT ratio abnormal (grade 3, 4.3%) |
80 mg/m2 2 times / day multiple, oral MTD Dose: 80 mg/m2, 2 times / day Route: oral Route: multiple Dose: 80 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
|
1 mg/kg 2 times / day multiple, oral Recommended Dose: 1 mg/kg, 2 times / day Route: oral Route: multiple Dose: 1 mg/kg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Fetal damage... AEs leading to discontinuation/dose reduction: Fetal damage (grade 4) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cheilitis | Disc. AE | 12.5 mg/kg single, oral Overdose Dose: 12.5 mg/kg Route: oral Route: single Dose: 12.5 mg/kg Sources: |
unhealthy, 29 |
Desquamation | Disc. AE | 12.5 mg/kg single, oral Overdose Dose: 12.5 mg/kg Route: oral Route: single Dose: 12.5 mg/kg Sources: |
unhealthy, 29 |
Headache | Disc. AE | 12.5 mg/kg single, oral Overdose Dose: 12.5 mg/kg Route: oral Route: single Dose: 12.5 mg/kg Sources: |
unhealthy, 29 |
Skin xerosis | Disc. AE | 12.5 mg/kg single, oral Overdose Dose: 12.5 mg/kg Route: oral Route: single Dose: 12.5 mg/kg Sources: |
unhealthy, 29 |
Skin xerosis | Disc. AE | 12.5 mg/kg single, oral Overdose Dose: 12.5 mg/kg Route: oral Route: single Dose: 12.5 mg/kg Sources: |
unhealthy, 29 |
Diarrhea | Disc. AE | 1000 mg single, oral Overdose |
unhealthy, 31 |
Anemia | grade 3, 11.1% DLT |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Emesis | grade 3, 11.1% DLT |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Hypercalcemia | grade 3, 11.1% DLT |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Thrombocytopenia | grade 3, 11.1% DLT |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Skin toxicity | grade 3, 33.3% DLT |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Hypercalcemia | grade 4, 22.2% DLT |
100 mg/m2 2 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Skin toxicity | grade 3, 17.4% DLT |
80 mg/m2 2 times / day multiple, oral MTD Dose: 80 mg/m2, 2 times / day Route: oral Route: multiple Dose: 80 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
AST/ALT ratio abnormal | grade 3, 4.3% DLT |
80 mg/m2 2 times / day multiple, oral MTD Dose: 80 mg/m2, 2 times / day Route: oral Route: multiple Dose: 80 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Emesis | grade 3, 4.3% DLT |
80 mg/m2 2 times / day multiple, oral MTD Dose: 80 mg/m2, 2 times / day Route: oral Route: multiple Dose: 80 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Hypercalcemia | grade 4, 4.3% DLT |
80 mg/m2 2 times / day multiple, oral MTD Dose: 80 mg/m2, 2 times / day Route: oral Route: multiple Dose: 80 mg/m2, 2 times / day Sources: |
unhealthy, 4 |
Fetal damage | grade 4 Disc. AE |
1 mg/kg 2 times / day multiple, oral Recommended Dose: 1 mg/kg, 2 times / day Route: oral Route: multiple Dose: 1 mg/kg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 26.8 uM] | ||||
yes [IC50 76.5 uM] | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/25039756/ |
yes | |||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/25039756/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25039756/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia]. | 1998 Sep |
|
All-trans retinoic acid-induced vasculitis and hemonecrosis of the ileum in a patient with acute promyelocytic leukemia. | 1999 Apr |
|
All-trans retinoic acid-induced multiple mononeuropathies. | 1999 Apr |
|
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. | 1999 Dec |
|
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. | 1999 Jul |
|
HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. | 1999 May 15 |
|
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells]. | 1999 Sep |
|
Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia. | 2000 Apr |
|
All trans retinoic acid induces apoptosis in acute promyelocytic NB4 cells when combined with isoquinolinediol, a poly(ADP-ribose) polymerase inhibitor. | 2000 Apr |
|
Effect of retinoic acid on the enhancing effect of acetaldehyde on mouse type I collagen expression. | 2000 Apr 1 |
|
2,3,7,8-tetrachlorodibenzo-p-dioxin increases serum and kidney retinoic acid levels and kidney retinol esterification in the rat. | 2000 Dec 1 |
|
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells. | 2000 Feb |
|
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. | 2000 Feb |
|
All-trans-retinoic acid-induced myositis: a description of two patients. | 2000 Feb |
|
The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. | 2000 Jan |
|
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. | 2000 Jul |
|
Regulation of retinoic acid signaling during lung morphogenesis. | 2000 Jul |
|
Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. | 2000 Jun |
|
Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. | 2000 Jun 20 |
|
[Severe side effects of the treatment of acute promyelocytic leukemia with all-trans retinoic acid]. | 2000 Jun 28 |
|
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. | 2000 Mar |
|
Differential regulation of apoptosis in normal versus transformed mammary epithelium by lutein and retinoic acid. | 2000 Mar |
|
Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma. | 2000 Mar |
|
Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation. | 2000 Mar |
|
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide]. | 2000 May |
|
Acute hepatomegaly with severe liver toxicity due to all-trans-retinoic acid. | 2000 May |
|
Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. | 2000 Nov |
|
Regulation of aquaporin-4 expression in astrocytes. | 2001 Apr 18 |
|
Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. | 2001 Aug 15 |
|
Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2. | 2001 Dec 7 |
|
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. | 2001 Jan 1 |
|
Analysis of cartilage-derived retinoic acid-sensitive protein in cerebrospinal fluid From patients With spinal diseases. | 2001 Jan 15 |
|
Regulation of IL-5 receptor on eosinophil progenitors in allergic inflammation: role of retinoic acid. | 2001 Jan-Mar |
|
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. | 2001 Jun |
|
Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT). | 2001 Jun 1 |
|
Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. | 2001 Jun 1 |
|
Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol. | 2001 Jun 29 |
|
1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. | 2001 May |
|
Retinoic acid prevents experimental Cushing syndrome. | 2001 Oct |
|
All-trans retinoic acid inhibits vascular smooth muscle cell proliferation targeting multiple genes for cyclins and cyclin-dependent kinases. | 2001 Sep |
|
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid. | 2001 Sep |
|
Gene-specific TCDD suppression of RARalpha- and RXR-mediated induction of tissue transglutaminase. | 2002 Jul |
|
Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2. | 2002 Jul 12 |
|
Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. | 2002 Jul-Aug |
|
Excentric cleavage products of beta-carotene inhibit estrogen receptor positive and negative breast tumor cell growth in vitro and inhibit activator protein-1-mediated transcriptional activation. | 2002 Jun |
|
Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. | 2002 Mar 15 |
|
[Genetic dissection of retinoic acid function in epidermis physiology]. | 2002 May |
|
Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis. | 2002 Sep |
|
All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia. | 2003 Mar 1 |
|
Effects of 9-cis retinoic acid on human homeobox gene NKX3.1 expression in prostate cancer cell line LNCaP. | 2006 Jul |
Patents
Sample Use Guides
acute promyelocytic leukemia (APL): The recommended dose is 45 mg/m2/day administered as two evenly divided doses until complete remission is documented. Therapy should be discontinued 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first.
acne vulgaris: RETIN-A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: the liquid may be applied using a fingertip, gauze pad, or cotton swab. If gauze or cotton is employed, care should be taken not to oversaturate it, to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16456186
Human bronchial SMCs were used and pretreated with or without tretinoin, also known as all-trans-retinoic acid (ATRA), (2 μM) for 20 min before the addition of PDGF (1 μg/ml), or ATRA alone. The neutral comet assay, which determines the incidence of double-stranded DNA breaks, was used to demonstrate that ATRA treatment induced apoptosis of bovine and human pulmonary artery SMC. In contrast, apoptotic cell death was not produced in response to ATRA in human bronchial airway SMC, as monitored by comet assay. Similarly, TUNEL assay and the measurement of mitochondrial membrane potential failed to demonstrate significant apoptosis by ATRA in airway SMCs. Positive controls, daunorubicin (DNR) and hydrogen peroxide, effectively elicited apoptosis in airway SMC. Because ATRA inhibited both morphologic and actin cytoskeletal changes induced by PDGF, it was characterized the effects of ATRA on PDGF-induced airway SMC migration using a modified Boyden chamber assay, which allows for determination of motility in random directions. PDGF caused a 4-fold increase in migration of airway SMCs after 24 h, and ATRA blocked these events. ATRA by itself had no effect. While the therapeutic level of ATRA in human plasma could reach 1–2 μM, the effects on airway SMC migration were observed with ATRA concentrations as low as 0.2 μM. DMSO, which is used as vehicle for ATRA and other retinoids, has no effect on PDGF-induced airway SMC migration. This does not appear to be due to the effects of ATRA on cell proliferation, as MTT assay showed that ATRA is not effective in inhibiting PDGF-induced cell proliferation; additionally, migration assay with 4 h of PDGF treatment also exhibits the ability of ATRA to inhibit migratory responses, as monitored using a modified Boyden chamber assay. Thus, although ATRA is ineffective in inhibiting proliferation and inducing apoptosis of airway SMCs, ATRA is an efficient inhibitor of airway SMC migration. Furthermore, using actinomycin D, a general inhibitor of gene transcription, showed that ATRA inhibition of SMC migration does not mediate gene transcriptional events.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:27 GMT 2025
by
admin
on
Mon Mar 31 17:34:27 GMT 2025
|
Record UNII |
5688UTC01R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007700
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NDF-RT |
N0000175607
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NCI_THESAURUS |
C68299
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
WHO-VATC |
QL01XX14
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
FDA ORPHAN DRUG |
71692
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NCI_THESAURUS |
C804
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
FDA ORPHAN DRUG |
5785
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
FDA ORPHAN DRUG |
165802
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
LOINC |
87673-0
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
WHO-VATC |
QD10AD51
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
FDA ORPHAN DRUG |
50990
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
WHO-ATC |
D10AD51
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NDF-RT |
N0000007700
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NDF-RT |
N0000007700
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
WHO-ATC |
D10AD01
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
WHO-VATC |
QD10AD01
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
WHO-ATC |
L01XX14
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NDF-RT |
N0000007700
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
NDF-RT |
N0000007700
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
||
|
LIVERTOX |
993
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL38
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
2722
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
m9558
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
2875
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
122758
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
15367
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
444795
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
5688UTC01R
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
221175
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
ALTERNATIVE | |||
|
C900
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
TRETINOIN
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
10753
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
DB00755
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
1674004
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
100000092588
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
Tretinoin
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
302-79-4
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
5688UTC01R
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
2644
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
2169
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
SUB11246MIG
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
DTXSID7021239
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
206-129-0
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY | |||
|
D014212
Created by
admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Binding Assay
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE |
Mediator Substance AOX1
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|